Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $16.50, but opened at $16.10. Telix Pharmaceuticals shares last traded at $16.12, with a volume of 13,152 shares traded.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on TLX shares. Wedbush reaffirmed an "outperform" rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Thursday, June 12th. William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals in a research report on Wednesday, March 12th. Finally, HC Wainwright assumed coverage on shares of Telix Pharmaceuticals in a report on Thursday. They set a "buy" rating and a $23.00 price objective for the company.
Check Out Our Latest Analysis on TLX
Telix Pharmaceuticals Stock Performance
The stock has a fifty day moving average of $16.97 and a two-hundred day moving average of $16.95. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 0.99.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Telix Pharmaceuticals stock. ABC Arbitrage SA acquired a new position in Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 26,939 shares of the company's stock, valued at approximately $451,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Featured Stories
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
